Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873247 | 0.75 | — | — | |
| SCHEMBL22497722 | 0.71 | BRD4 (0.33) | BRD4BRD2GAALMNASMN1; SMN2 | |
| SCHEMBL27439659 | 0.68 | BRD4 (0.38) | BRD4BRD2 | |
| Hydrochloric Acid SCHEMBL27294572 | 0.68 | CYP1A2 (0.34) | BRD4BRD2LMNA | |
| SCHEMBL2198294 | 0.68 | LMNA (0.32) | BRD4BRD2GAALMNASMN1; SMN2 | |
| SCHEMBL3417324 | 0.67 | GAA (0.37) | BRD4BRD2GAALMNA | |
| SCHEMBL8394520 | 0.66 | MAPT (0.39) | BRD4BRD2GAALMNA | |
| SCHEMBL2617349 | 0.64 | — | — | |
| SCHEMBL18250371 | 0.63 | — | — | |
| SCHEMBL27925912 | 0.63 | ELANE (0.36) | BRD4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117321053-A | P300 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116547277-A | P300 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-115054600-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114984003-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-109415321-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | BRD4 1565/4885BRD2 775/4885GAA 2130/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | BRD4 1565/4885BRD2 775/4885GAA 2130/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | BRD4 710/4885BRD2 1925/4885GAA 337/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | BRD4 1561/4885BRD2 785/4885GAA 2153/4885 |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | CYP19A1, PGR, GNRHR | BRD4 2450/4885BRD2 2292/4885GAA 4776/4885 |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | BRD4 1879/4885BRD2 2160/4885GAA 2344/4885 |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | BRD4 1565/4885BRD2 775/4885GAA 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.